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There are several antiproliferative and angiogenic factors, recently have been discovered (IL-27, IL-29, IL-31 and IL-33), but they 
have not been tested yet in lung cancer patients. The aim of this pilot study was to assess the clinical usefulness of determination of IL-
27, IL-29, IL-31 and IL-33 in advanced stages of lung cancer. Patients and Methods: The study included 45 patients (38 males; mean 
age 62 years; 45 with advanced NSCLC). Serum and BALF cytokine concentrations were evaluated by ELISA method before che-
motherapy. The comparative groups consisted of patients with sarcoidosis (BBS, n = 15), hypersensivity pneumonitis (HP, n = 8) and 
healthy subjects (n = 15). Results: The serum IL-29 levels were higher in NSCLC patients than in the sarcoidosis group. However, 
serum IL-27, IL-31 and IL-33 did not differ markedly between: NSCLC, BBS, HP and the control group. Concentrations of IL-
29 and IL-31 in BALF did not differ significantly between investigated groups. In all groups levels of IL-27 and IL-29 are signifi-
cantly higher in serum than in BALF. Concentrations of IL-31 in BBS, HP and control groups tended to higher in BALF than 
in serum. These differences were significantly in NSCLC patients. Patients in stage IIIB of NSCLC had higher serum levels of IL-
29 than these in stage IV. Lung cancer patients with partial remission (PR) after chemotherapy had significantly higher concentration 
of IL-27 in BALF than patients with SD. However, patients with SD had higher levels of IL-29 in BALF than patients with PD. A neg-
ative correlation was found between serum IL-31 levels before therapy and time to progression of NSCLC. Conclusion: Determination 
of IL-27, IL-29 and IL-31 in serum and BALF can be useful in clinical practice, but their practical significance needs further studies.
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Inﬂammation and angiogenesis are closely associ­
ated, and pathologic angiogenesis has been implicated 
on the development of chronic inﬂammatory diseases 
and several cancers. Interplay between inﬂammation 
and angiogenesis is mediated largely by growth factors 
and cytokines, particularly interleukins [1].
Neoangiogenesis plays a vital role in the tumor 
growth and the development of metastasis [2]. Re­
cently there have been discovered several antiproli­
ferative and angiogenic factors, but they have not been 
tested yet in lung cancer patients. Some of them are: 
IL­27, IL­29, IL­31 and IL­33. 
IL­27 has been associated mainly with the dif­
ferentiation of Th1 lymphocytes, enhancement of the 
cellular type immune response and the reciprocal 
inhibition of Th2 humoral immune reactions [3]. The 
IL­27 acts as an inhibitor of angiogenesis, stimulates 
the expression of IFN­gamma­inducing protein (IP­
10/CXCL10) and a monokine induced by IFN­gamma 
(MIG/CXCL9). Both molecules were reported to inhibit 
tumor growth and metastasis. Only a small percentage 
of vascular endothelial cells in normal tissues is posi­
tive for CXCR3 (CXC­Chemokine receptor 3), which 
is a receptor for IL­27­induced CXCL10, whereas the 
frequency of CXCR3­positive cells in neoplastic tissues 
is much higher than in normal ones [4].
IL­29, designated as a type III interferon (IFN), has 
been recently identiﬁed the class II cytokine receptor 
ligands that are distantly related to members of the 
IL­10 family and the type I IFN family [5]. Interferons 
are a large family of proteins having a wide variety 
of biological properties [6]. These include inhibition 
of cell growth, activation of T cell and natural killer (NK) 
cell cytotoxicity, promotion of T helper type I responses 
and inhibition of angiogenesis [7]. The crucial to the 
antiproliferative effect of IL­29 on non­small cell lung 
cancer (NSCLC) is the upregulation of p21 expression 
and induction of apoptosis [8]. Actually, p21 expres­
sion in NSCLC tumors has been reported to be a pre­
dictor for a favorable prognosis [9].
IL­31 is a recently discovered cytokine, belonging 
to the gp130/IL­6 cytokine family that includes IL­6, vi­
ral IL­6, IL­11, IL­27 [10]. IL­31 is an immunoregulatory 
cytokine that is mainly produced by activated Th cells 
[11]. IL­31 acts through the heterodimeric receptors 
of IL­31 (IL­31R) and oncostatin receptor (OSMR) 
which are expressed on IL­31 activated monocytes 
and expressed on epithelial cells [11]. Bronchial and 
alveolar epithelial cells, pulmonary ﬁbroblasts and 
macrophages are the primary targets of IL­31 in the 
lung [12]. IL­31 can signiﬁcantly elevate the gene and 
protein expressions of epidermal growth factor (EGF) 
and vascular endothelial growth factor (VEGF) [13]. 
A recent study demonstrated that IL­31 is highly ef­
fective in suppressing the prolifeation of lung epithelial 
cells by up­regulating p27Kip1 (cyclin­dependent 
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kinase inhibitor p27 Kip1) and down­regulating cyclin 
B1, cdc2, cdk6, mcm4 and Rb [14]. 
IL­33 is a newly identiﬁed cytokine of the IL­1 fam­
ily, which also includes the inﬂammatory cytokines IL­
1α, IL­1β, and IL­18 [15]. It has been shown to signal 
via ST2 receptor. IL­33 expression is broadly detected 
in various tissues, including stomach, lung, spinal cord, 
brain, and skin, as well as in cells, including smooth 
muscle cells and epithelial cells lining bronchus [16]. 
On the basis of current reports very little is known 
about cellular sources of IL­33. Recent publications 
imply that vascular endothelial cells are the dominant 
IL­33­expressing cell population in vivo [17]. Choi et al. 
[18] have shown that IL­33 promotes angiogenesis and 
endothelial permeability in an endothelium­derived 
NO­dependent manner.
In our study, we measured the serum and BALF 
(bronchoalveolar lavage fluid) levels of IL­27, IL­29, IL­
31 and IL­33 in lung cancer patients and assessed their 
inter­relationship and clinical signiﬁcance. We also 
measured levels these cytokines (comparative groups) 
in patients with sarcoidosis, hypersensivity pneumoni­
tis (HP) and healthy persons. Our study provides new 
insight into the mechanism of function new angiogenic 
cytokines in lung cancer. 
MATERIALS AND METHODS
Patients. The study involved 45 patients diag­
nosed with the histological diagnosis of NSCLC and 
treated in the Department of Lung Diseases and Tu­
berculosis in Bialystok (38 male patients). The mean 
age of patients was 61.9 ± 4 years. At the beginning 
of the study patients had neither been treated with any 
anticancer medication nor undergone radiotherapy. 
Squamous cell carcinoma (SCC) comprised 48.8% 
(22 individuals) of patients with NSCLC, adenocar­
cinoma was revealed in 20% (9 patients), whereas 
NSCLC was diagnosed in 31.1% (14 patients). After 
four cycles of chemothe rapy partial remission (PR) 
was reported in 19 patients (42.2%), stabilization (SD) 
in 11 patients (24.4%), and progression of disease 
(PD) in 15 patients (33.3%). Serum samples obtained 
from the whole blood of patients with lung cancer 
taken before chemotherapy were used. To exclude the 
possible interference of chemotherapy, subsequent 
blood samples were obtained at least 28 days after 
the last administration of cytotoxic drugs. Blood serum 
was stored at ­80 °C until the assay. At the ﬁrst stage, 
blood samples were taken to assess IL­27, IL­29, IL­
31 and IL­33 after complete diagnostics of lung cancer 
had been made, including X­ray and CT of the chest, 
bronchoﬁberscopy with H­P test, lung transbronchial 
biopsy (TBB), or transbronchial needle aspiration bi­
opsy (TBNA). The clinical analysis comprised the 
evaluation of clinical staging of NSCLC (TNM, IASLC), 
and the performance stage according to Zubrod. The 
response to therapy was estimated after four cycles 
of chemotherapy according to the RECIST (Response 
Evaluation Criteria in Solid Tumors) criteria [19]. All 
patients underwent basic laboratory tests and acces­
sory investigations (ultrasonography of the abdominal 
cavity, if necessary, of the chest, EEG, and CT of the 
central nervous system).
The comparative groups in study consisted of 15 pa­
tients with pulmonary sarcoidosis (BBS, Besnier­
Boeck­Schaumann disease) and 8 with HP (extrinsic 
allergic alveolitis). BBS patients were in the second 
stage of the disease (confirmed by X­Ray of the chest, 
High Resolution Computed Tomography of the lung and 
histological examination) [20]. Patients with HP were 
in subacute stage, confirmed by HRCT of the chest, 
alveolitis in BAL, exposure history of known offending 
antigen. BBS and HP patients were lifetime nonsmok­
ers and did not experience any acute respiratory illness 
during the 6 weeks prior to the study. They had neither 
been treated with glucocorticoid medication.
Bronchoscopy and BALF analysis in all patients and 
control group processing were performed as a part 
of routine clinical management, according to the rec­
ommended guidelines [21]. Subjects underwent bron­
choscopy by flexible fiberoptic bronchoscope (Pentax 
FB 18 V; Pentax Corporation, Tokyo, Japan). Subjects 
received atropine (0.5 mg, i.m.), and midazolam (5 mg, 
i.m.). Local anesthesia was performed by inhalation 
of an aerosol solution of 22 ml of 2% lidocaine 15 min 
before broncho scopy. The bronchoscope was in­
serted and wedged in the right middle lobe, and three 
50 ml aliquots of sterile saline solution, warmed to 37 °C, 
were instilled into the subsegmental bronchus. Fluid 
was gently aspirated immediately after each aliquot 
was introduced, and collected in a sterile container. 
A second 50 ml aliquot of recovered fluid was labeled 
as BALF. BALF samples were analyzed for total and dif­
ferential cell counts, flow cytometry to measure CD4+, 
and CD8+ lymphocyte counts, and for IL­27, IL­29, IL­
31 and IL­33 levels detected by ELISA.
During bronchoscopy, oxygen saturation and 
ECG tracings were continuously monitored. One 
aliquot was reserved for a total cell number using Na­
geotte’s chamber and these results were expressed 
as 105 cells/ml. The remaining fluid was immediately 
centrifuged at 800 rpm for 10 min at 4 °C. The cell 
pellet was washed twice with phosphate­buffered 
saline solution (without Ca2++ and Mg2++). Cytocen­
trifugates were stained by the May­Grunwald Giemsa 
method. The differential cell count of macrophages, 
neutrophils, lymphocytes, eosinophils, and epithelial 
cells was made using light microscopy (magnification 
x 1000) by counting at least 400 cells. Two obser­
vers blinded to the patients’ characteristics counted 
400 cells to determine the differential cell count.
In accordance with the declaration of Helsinki, the 
study protocol was approved by the local ethics com­
mittee and written informed consent was obtained 
from all participants.
Control subjects. The control group for serum 
and BALF analysis consisted of 15 healthy volunteers 
(13 men, 2 women) without any acute or chronic 
inﬂammatory conditions. The mean age of controls 
at the time of sampling was 60.1 ± 5. There were 
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no signiﬁcant differences in age and sex between 
patients and controls.
NSCLC patients’ therapy. Chemotherapy was 
carried out in a 21­day cycle using cisplatin at a dose 
of 30 mg/m2 on days 1, 2, and 3 and gemcytabine 
at a dose of 1000 mg/m2 on days 1 and 8 of the cycle. 
All patients received four cycles of chemotherapy. 
Some of the patients underwent later radiotherapy 
or next cycles of chemotherapy.
Serum and BALF IL-27, IL-29, IL-31 and IL-
33 analysis. IL­27, IL­29, IL­31 and IL­33 concentra­
tions were determined by means of enzyme­linked 
immunosorbent assay (ELISA) method according 
to the manufacturer’s instructions.
All specimens were assayed twice and the average 
of the two measurements was used in the data analy­
sis. Values were considered positive if they were twice 
that of the background with a responding coefficient 
of variation of less than 10%.
The minimum detectable dose (MDD) of IL­27 (US­
CNK Life Science Inc.), IL­29 (eBioscience®), IL­31 (eBio­
science®) and IL­33 (eBioscience®) was respectively 
6.1 pg/ml, 2.0 pg/ml, 1.0 pg/ml and 0.2 pg/ml. 
Statistical analysis. Statistical analysis was per­
formed using Statistical 10.0 software. Data distribution 
was analysed with Shapiro Wilk W test. Student’s t test for 
depended or independed data was used to compare the 
respective groups and pairs to compare features in two 
time intervals. Mann — Whitney’s test and Wilcoxon’s test 
were used for the features inconsistent with this distribu­
tion. Correlations between the parameters were calcu­
lated by the Spearman’s rank test. Survival curves were 
generated using the Kaplan — Meier’s method, and the 
signiﬁcance of the difference in survival rates was de­
termined by the log­rank test. Multivariate analysis was 
performed using a Cox’s proportional hazards model. All 
patients with lung cancer were divided into two groups 
according to their IL­27, IL­29, IL­31 and IL­33 serum 
levels. The cut­off point was set at 32.85 pg/ml for se­
rum IL­27, 70.17 pg/ml for serum IL­29, 12.29 pg/ml for 
serum IL­31 and 5.13 pg/ml for serum IL­33 concentra­
tions. Receiver­operating characteristics (ROC) curves 
were applied to ﬁnd the cut­off level of IL­27, IL­29, 
IL­31 and IL­33.
Time to progression (TTP) was defined as the time 
from randomization (diagnosing) until objective tumor 
progression (www.cancer.gov, www.fda.gov). A value 
of p < 0.05 was considered to be the level of statistical 
signiﬁcance.
RESULTS
None of the prognostic parameters for NSCLC 
patients analyzed in the study was correlated sig­
nificantly with the serum IL­27, IL­29, IL­31 and IL­
33 levels (Table 1). The levels of IL­27, IL­29, IL­31 and 
IL­33 in serum and BALF are shown in Table 2. The 
baseline serum IL­29 levels were significantly higher 
in patients with advanced NSCLC than in the BBS 
group (p = 0.043). However, serum IL­27, IL­31 and 
IL­33 did not differ markedly between: NSCLC, BBS, 
HP and the control group (Table 2).
Table 1. Patients’ characteristics
Parameter NSCLC BBS HP Control
No. of patients 45 15 8 15
Age, year mean ± SD 61.9±4 58.3±3 59.5±2 60.1±5
Gender, male/female 38/7 13/2 7/1 13/2
Weight loss (10%), yes/no 19/26 0 0 0
Performance status, 0–1/2 30/15 15 15 15
Histology, squamous cell/other 22/23 15 histology 
confirmed 
BBS
0 0
Stage, IIIB/IV/other 18/27 stage II  
of BBS
subacute 
HP
/-/
Hemoglobin (12 g/dl), low/
normal
13/32 0/15 0/8 0/15
Albumin (3.5 g/dl), low/normal 9/36 0/15 0/8 0/15
LDH (450 U/L), normal/elevated 28/17 15/0 8/0 15/0
Response to chemotherapy, 
yes/no
30/15 /-/ /-/ /-/
Abbreviation: No = number; numerical data are shown as mean ± stan-
dard deviation
Table 2. Distribution of serum IL-27, IL-29, IL-31 and IL-33 values in pa-
tients and controls
Concentration
Median Range
NSCLC 
(n=45) BBS (n=15) HP (n=8)
Control 
(n=15)
SE
RU
M
IL-27 (pg/ml) 17.69 
16.0–193.6a
17.41 
16.0–273.3b
17.69 
16.5–21.7c
16.85 
16.0–284.1d
IL-29 (pg/ml) 43.2 
14.5–154.8e
35.22 
18.8–81.6f
43.14 
18.8–378.5g
45.17 
5.7–111.3h
IL-31 (pg/ml) 10.0 
5.1–18.0i
9.59 
6.8–17.3
8.72 
6.3–10.5
10.09 
7.3–14.8
IL-33 (pg/ml) 2.83 
0.4–14.0
2.77 
0.5–27.7
8.05 
1.1–16.1
2.23 
0.7–9.6
BA
LF
IL-27 (pg/ml) 14.99 
14.7–86.8j
14.29 
14.1–15.2k
14.62 
14.5–15.1l
13.84 
13.7–15.0m
IL-29 (pg/ml) 20.49 
8.2–37.2n
20.40 
12.4–31.8o
23.36 
16.5–31.8p
18.53 
12.4–29.9r
IL-31 (pg/ml) 11.56 
6.3–13.9s
11.73 
10.2–12.7
11.75 
5.0–12.9
11.17 
5.8–13.7
IL-33 (pg/ml) 2.92 
1.1–84.5t
4.32 
2.6–6.2u
5.65 
0.1–12.5
3.38 0.6– 
56.9
avsj p=0.00001 dvsm p = 
0.0009
fvso p = 
0.001
ivss p = 0.02 lvsm p = 
0.014
bvsk p = 0.001 evsf p = 
0.043
gvsp p = 
0.035
jvsm p = 
0.016
tvsu p = 
0.015
cvsl p = 0.011 evsn p = 
0.0002
hvsr p = 
0.002
kvsm p = 
0.005
Abbreviations: HP — hypersensitivity pneumonitis, extrinsic allergic alveolitis; 
n — number; IL — interleukin.
Patients with NSCLC, BBS and HP had the con­
centrations of IL­27 in BALF at the same level. How­
ever, these concentrations were significantly higher 
than in controls. NSCLC patients also had markedly 
lower levels of IL­33 in BALF than patients with BBS 
(p = 0.015). Concentrations of IL­29 and IL­31 in BALF 
did not differ significantly between investigated 
groups. In all groups levels of IL­27 and IL­29 are 
significantly higher in serum than in BALF. Concentra­
tions of IL­31 in BBS, HP and control groups tended 
to higher in BALF than in serum. These differences 
were significant in NSCLC patients (p = 0.02) (Table 2).
The serum levels of IL­29 were higher in group IIIB 
NSCLC than in group IV NSCLC (p = 0.034) (Table 3). 
We also observed a tendency to lower concentrations 
of IL­29 in BALF, but differences were not significant. 
Patients in group IIIB had the same concentrations 
of IL­27, IL­31 and IL­33 as patients in group IV (Table 4).
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Table 3. The serum and BALF levels of IL-27, IL-29, IL-31 and IL-33 be-
fore chemotherapy in group IIIB and group IV NSCLC patients
Concentra-
tion
III B NSCLC (n = 18) IV NSCLC (n = 27)
Serum BALF Serum BALF
IL-27 (pg/ml) 18.26 
16.5–75.9
14.91 
14.6–186.8
17.13 
16.0–193.6
14.99 
14.7–102.4
IL-29 (pg/ml) 62.66 
18.8–154.8a
18.53 
10.3–29.9
43.20 
14.5–92.8b
20.49 
8.2–37.2
IL-31 (pg/ml) 9.59 
5.1–14.3
11.36 
6.9–12.9
10.34 
6.6–18.0
11.56 
6.3–13.9
IL-33 (pg/ml) 3.77 
0.4–14.0
2.69 1.1–6.7 2.57 0.7–9.3 3.15 
1.8–84.5
Abbreviations: avsb p = 0.034. 
Table 4. The serum levels of IL-27, IL-29, IL-31 and IL-33 before chemo-
therapy in relation to response to treatment
Concentration 
in serum
Response to chemotherapy
PR (n = 19) SD (n = 11) PD (n= 15)
IL-27 (pg/ml) 17.69 (16.5–31.8) 17.13 (16.0–37.2) 17.69 (16.5–193.6)
IL-29 (pg/ml) 43.2 (18.8–154.8) 39.23 (14.5–85.4) 47.14 (27.1–104.0)
IL-31 (pg/ml) 9.34 (5.1–14.3) 10.59 (8.3–18.0) 10.34 (8.8–16.3)
IL-33 (pg/ml) 2.83 (0.7–14.0) 4.31 (1.6–13.1) 2.0 (0.4–9.3)
Abbreviations: PR — partial response; SD — stable disease; PD — progres-
sive disease.
In the group of NSCLC patients, PR was reported 
in 19 patients (42.2%), SD in 11 patients (24,4%), and 
PD in 15 patients (33.3%). No correlation was found 
between the serum concentrations of IL­27, IL­29, IL­
31 and IL­33 before therapy and the effect of chemo­
therapy (Table 5). Lung cancer patients with PR after 
chemotherapy had significantly higher concentration 
of IL­27 in BALF (before treatment) than patients with 
SD (p = 0.006). However, patients with SD had higher 
levels of IL­29 in BALF than patients with progressive 
disease (p = 0.048). No correlation was found between 
the BALF concentrations of IL­31 and IL­33 and the 
effect of chemotherapy (Table 6).
Table 5. BALF levels of IL-27, IL-29, IL-31 and IL-33 before chemotherapy 
in relation to treatment response
Concentration 
in BALF
Response to chemotherapy
PR (n = 19) SD (n = 11) PD (n= 15)
IL-27 (pg/ml) 16.06 (14.8–86.8a) 14.92 (14.6–19.6b) 14.95 (14.7–102.4
IL-29 (pg/ml) 20.49 (8.2–37.2) 22.42 (14.5–28.1c) 19.51 (10.3–26.2d)
IL-31 (pg/ml) 11.95 (6.9–13.9) 11.17 (10.5–12.7) 11.36 (6.3–12.1)
IL-33 (pg/ml) 3.15 (1.1–84,5) 3.15 (1.8–8.3) 2.92 (2.0–11.7)
Abbreviations: PR — partial response; SD — stable disease; PD — progres-
sive disease; avsb p = 0.006; cvsd p = 0.048. 
Table 6. Inﬂuence of statistically signiﬁcant prognostic factors and serum 
parameters on survival in patients with advanced NSCLC 
Prognostic factor p value
Age 0.025
Weight loss 0.002
Performance status 0.001
Serum IL-27 0.657
Serum IL-29 0.765
Serum IL-31 0.456
Serum IL-33 0.732
BALF IL-27 0.345
BALF IL-29 0.451
BALF IL-31 0.421
BALF IL-33 0.527
A negative correlation was found between se­
rum IL­31 levels before therapy and TTP of NSCLC 
(R = ­0.45; p = 0.038) (Figure).
When all patients with lung cancer were divided 
into high and low groups using cut­off serum and 
BALF IL­27, IL­29, IL­31 and IL­33 concentrations, the 
prognoses of high and low groups were not different. 
The cut­off serum concentrations were 30.85 pg/ml 
(IL­27), 70.17 pg/ml (IL­29), 12.29 pg/ml (IL­31) and 
5.13 pg/ml (IL­33). The cut­off BALF concentra­
tions were 14.93 pg/ml (IL­27), 12.67 pg/ml (IL­29), 
12.97 pg/ml (IL­31) and 4.78 pg/ml (IL­33). The medi­
an survival of patients from all groups was 10.7 months.
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Figure. Serum IL­31 levels in relation to time to NSCLC pro­
gression
Older age, weight loss, and performance status 
yielded prognostic value (Table 6). Conversely, neither 
IL­27, IL­29, IL­31 nor IL­33 levels (serum and BALF) 
have proven to be signiﬁcant for survival.
In NSCLC group a negative correlation was found 
between serum levels of IL­33 and levels of IL­
27 in BALF (R = ­0.44, p = 0.005).
We didn’t found any correlation between the levels 
of the same cytokine in serum and BALF. The differen­
tial cell profiles in BALF are shown in Table 7. Patients 
with NSCLC had the highest percentage and number 
of macrophages (p < 0.05). Patients with BBS had 
the highest percentage and number of lymphocytes.
Table 7. Differential cell profiles in BALF
Median Range p, va-
lue
NSCLC 
(n=45) 
BBS 
(n=15) HP (n=8)
Control 
(n=15)
Total cell: 
104 cell/ml
65.0  
(25–200)
70.0  
(40–120)
95.0  
(50–170) 
55.0  
(40–155)
p<0.05
Macrophages, % 80.97  
(15–95)
65.0  
(42–94)
33.0  
(17–45)
80.0  
(22–90)
p<0.05
n x 104/ml 52.0 
(9.7–61.7) 
45.5 
(29.4–65.8
31.35 
(16.1–42.7)
44.0 
(12.1–49.5)
p<0.05
Lymphocytes, % 9.0 (2–49) 33.0  
(4–56)
63.0  
(53–82)
18.0  
(8–38)
p<0.05
n x 104/ml 5.85 
(1.3–31.8)
23.1 
(2.8–39.2)
59.85 
(50.3–77.9)
9.9 
(4.4–20.9)
p<0.05
Neutrophils, % 1.0  
(0–760)
1.0 
(0–1.0)
1.0 (0–3) 0 /-/
n x 104/ml 0.65 
(0–49.4)
0.7 
(0–0.7)
0.95 
(0–2.85)
0 /-/
Eosinophils, % 1.0 (0–6) 1.0 (0–1) 1.0 (0–2) 0 /-/
n x 104/ml 0.65 
(0–3.9)
0.7 
(0–0.7)
0.95 
(0–1.9)
0 /-/
DISCUSSION
Tumor growth and metastases formation is con­
trolled by several pathological processes and are 
mediated by inhibitors and stimulators. In NSCLC 
group the negative correlations between serum levels 
of IL­33 and levels of IL­27 in BALF, obtained in our 
study, prove mutual inter­relations between factors 
mentioned above.
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To our knowledge, this is the ﬁrst report on serum and 
BALF levels of IL­27, IL­29, IL­31 and IL­33 in NSCLC 
determined by ELISA technique.
In our study, concentrations of antyproliferative and 
antyangiogenic factors such as IL­27, IL29, were lower 
in BALF than in serum. We observed a tendency for the 
highest concentrations of IL­27 and IL­29 (serum and 
BALF) in NSCLC group. This reflects a weaker local 
(BALF) than systemic (in serum) immune/antyprolifera­
tive response. The high levels of IL­27, IL­29 in NSCLC 
provide a particularly weakened defense mechanism 
in cancer patients. Moreover, it is well known that cancer 
patients have the most severe angiogenesis. Higher 
le vels of IL­27 in serum than in BALF may be due to the 
origin of this cytokine. It may be released from endo­
thelial cells, hematopoietic cells, Th17 lymphocytes, 
B lymphocytes, and NK cells [22–24]. This can be also 
the likely reason for higher BALF concentrations of IL­
27 in BBS than healthy individuals. Increased expression 
of IL­27 in sarcoidosis patients was observed by Larous­
serie et al. [25]. It is known about the increased angio­
genic activity in patients with sarcoidosis [26]. Sekiya 
et al. [26] concluded that serum VEGF values in patients 
with sarcoidosis are a predictive factor in determining 
extrathoracic organ involvement and as a parameter that 
determines the treatment with corticosteroid. Serum 
VEGF might be a useful prognostic marker in sarcoid­
osis. The results of our study are in accordance with the 
ﬁndings of Sekiya et al. [26] because BALF levels of IL­33, 
proangiogenic factor, were higher in BBS patients than 
in NSCLC. The results of our study in NSCLC group are 
in accordance with the ﬁndings of other authors based 
on TNF­alfa (tumor necrosis factor­alpha) [27].
ROC curve analysis did not confirm the usefulness 
of IL­27, IL­29, IL­31 and IL­33 concentrations in se­
rum and BALF for lung cancer diagnostics.
In our study, the serum levels of IL­29 were higher 
in group IIIB NSCLC than in group IV NSCLC. These 
ﬁndings are in conformity with the studies of Singhal 
S et al. [28]. The crucial to the antiproliferative effect 
of IL­29 on NSCLC is upregulation of p21 expression 
which has been reported to be a predictor for a favorable 
prognosis [28] Patients in stage IIIB have better progno­
sis than in stage IV (patients with distant metastases).
We showed that BALF IL­27 concentration before 
treatment was markedly higher in patients with PR af­
ter chemotherapy than in those with SD. Moreover, 
patients with SD had higher BALF levels of IL­29 than 
patients with PD. We have shown that higher con­
centrations of inhibitors of tumor growth in BALF may 
contribute to response to chemotherapy. The results 
of our study are in accordance with the data of Shimizu 
et al. [9]. This study [9] has shown that malignant 
melanoma cells transfected with IL­27 genes had lower 
VEGF levels and reduced vasculature in lung metasta­
sis compared with animals cells that did not express 
IL­27. Therefore, IL­27 can inhibit tumor progression 
by several mechanisms simultaneously, regardless 
of tumor immunogenicity, potentially making it a valu­
able therapeutic tool in poorly immunogenic tumors. 
Importantly, IL­27 inhibits the growth of both primary 
tumors and metastases [29]. Moreover, IL­27 may 
also inﬂuence other cells, including Th7 lymphocytes, 
B lymphocytes, and NK cells [22–24].
Newly identiﬁed cytokine, IL­29 is considered 
to belong to the IFN family and designed as type III 
IFN. In addition to its primarily reported antiviral activity, 
type III IFN has also been shown to have direct antitu­
mor action against several human tumor lines including 
colon cancer [30] and esophageal carcinoma [31]. 
There are no data about serum, BALF concentrations 
of IL­27 and IL­29 in NSCLC patients.
In our study, we found a negative correlation be­
tween serum IL­31 levels before therapy and time 
to NSCLC progression (after chemotherapy). We con­
firm the results of study of Ip et al. [13] which have 
shown that IL­31 can signiﬁcantly elevate the gene and 
protein expressions of EGF and VEGF [13].
In conclusion, patients in stage IIIB of NSCLC had 
higher serum levels of IL­29 than in stage IV. Higher 
BALF levels of IL­27 or IL­29 before therapy may suggest 
a better response to chemotherapy. Higher serum levels 
of IL­31 before therapy may suggest shorter TTP. Our 
results require confirmation in a larger group of patients. 
Determination of IL­27, IL­29 and IL­31 in serum and 
BALF can be useful in clinical practice, but their practical 
significance needs further studies.
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